Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6354593 | 0.86 | MEN1 (0.46) | MEN1ALDH1A1KMT2A | |
| SCHEMBL6198975 | 0.78 | MEN1 (0.36) | MEN1ALDH1A1KMT2A | |
| SCHEMBL6197297 | 0.76 | MEN1 (0.37) | MEN1ALDH1A1KMT2A | |
| SCHEMBL4686234 | 0.71 | ALDH1A1 (0.50) | MEN1ALDH1A1KMT2A | |
| SCHEMBL6352896 | 0.71 | MEN1 (0.38) | MEN1ALDH1A1KMT2A | |
| SCHEMBL6343283 | 0.71 | MEN1 (0.38) | MEN1ALDH1A1KMT2A | |
| SCHEMBL15932248 | 0.70 | MEN1 (0.54) | MEN1ALDH1A1KMT2A | |
| SCHEMBL6274020 | 0.70 | MEN1 (0.37) | MEN1ALDH1A1KMT2A | |
| SCHEMBL21111103 | 0.68 | MEN1 (0.46) | MEN1ALDH1A1KMT2A | |
| SCHEMBL4551571 | 0.68 | MEN1 (0.42) | MEN1ALDH1A1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-2004532799-A | — | — | 2004-10-28 | — | — | JP | claimed |
| EP-1363879-A2 | SULFIDE AND DISULFIDE COMPOUNDS AND COMPOSITIONS FOR CHOLESTEROL MANAGEMENT AND RELATED USES | Esperion Therapeutics Inc. (US) | 2003-11-26 | — | — | EP | claimed |
| US-20020077316-A1 | Sulfide and disulfide compounds and compositions for cholesterol management and related uses | ESPERION THERAPEUTICS, INC. | 2002-06-20 | — | — | US | claimed |
| WO-2002030884-A2 | SULFIDE AND DISULFIDE COMPOUNDS AND COMPOSITIONS FOR CHOLESTEROL MANAGEMENT AND RELATED USES | ESPERION THERAPEUTICS, INC. (US) | 2002-04-18 | — | — | WO | claimed |
| US-20050020694-A1 | Sulfide and disulfide compounds and compositions for cholesterol management and related uses | ESPERION THERAPEUTICS, INC. | 2005-01-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020077316-A1 | Sulfide and disulfide compounds and compositions for cholesterol management and related uses | GSS, IAPP, STS | MEN1 3008/4885ALDH1A1 2827/4885KMT2A 3706/4885 |
| US-20050020694-A1 | Sulfide and disulfide compounds and compositions for cholesterol management and related uses | GSS, STS, CBS | MEN1 2869/4885ALDH1A1 2643/4885KMT2A 3715/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.